Home › Funds › RAFFLES ASSOCIATES LP › LCTX
RAFFLES ASSOCIATES LP position in LCTX
LINEAGE CELL THERAPEUTICS IN · Health Care
RAFFLES ASSOCIATES LP reported holding 5,197,788 shares of LCTX (LINEAGE CELL THERAPEUTICS IN) in its Q3 2026 13F filing — a position valued at US$5.0M, representing 4.25% of its reported portfolio and ranking #7 among its reported holdings. RAFFLES ASSOCIATES LP has disclosed LCTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How RAFFLES ASSOCIATES LP's LCTX position evolved
RAFFLES ASSOCIATES LP first disclosed a stake in LCTX in Q3 2023 at 1,587,739 shares (US$1.9M). The position peaked in Q3 2025 at 5,387,788 shares, worth US$9.1M. Across 13 filings, RAFFLES ASSOCIATES LP increased the stake 6 time(s), trimmed it 2 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 5,197,788 shares valued at US$5.0M. Notable position changes include a 34% increase in Q4 2023 (shares rose 36% over the following quarter), a 51% increase in Q1 2024 (shares fell 32% over the following quarter), a 36% increase in Q2 2024 (shares fell 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.59M | $1.87M | New |
| Q4 2023 | 2.13M | $2.32M | Add |
| Q1 2024 | 3.21M | $4.75M | Add |
| Q2 2024 | 4.36M | $4.35M | Add |
| Q3 2024 | 4.51M | $4.08M | Add |
| Q4 2024 | 5.49M | $2.76M | Add |
| Q1 2025 | 5.64M | $2.55M | Add |
| Q2 2025 | 5.39M | $4.89M | Reduce |
| Q3 2025 | 5.39M | $9.11M | Hold |
| Q4 2025 | 5.36M | $8.96M | Hold |
| Q1 2026 | 5.36M | $8.47M | Hold |
| Q2 2026 | 5.20M | $6.81M | Reduce |
| Q3 2026 | 5.20M | $4.97M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LCTX and 13F data
LCTX (LINEAGE CELL THERAPEUTICS IN) is a Health Care company. 28 other funds we track also report a position in LCTX — the largest reported positions include BROADWOOD CAPITAL INC (US$47.4M), Defender Capital, LLC. (US$6.4M), Connective Capital Management, LLC (US$281K). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LCTX
- BROADWOOD CAPITAL INC 49.56M sh · $47.37M · Q3 2026
- Defender Capital, LLC. 6.65M sh · $6.35M · Q3 2026
- Connective Capital Management, LLC 293.62K sh · $280.62K · Q3 2026
More on RAFFLES ASSOCIATES LP
FAQ
How long has RAFFLES ASSOCIATES LP held LCTX?
RAFFLES ASSOCIATES LP has disclosed LCTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is RAFFLES ASSOCIATES LP's current position in LCTX?
As of Q3 2026, RAFFLES ASSOCIATES LP holds 5.20M shares of LCTX (LINEAGE CELL THERAPEUTICS IN), valued at $4.97M, representing 4.25% of its reported portfolio and ranking #7.
Has RAFFLES ASSOCIATES LP been buying or selling LCTX?
In the latest 13F filing (Q3 2026), RAFFLES ASSOCIATES LP held unchanged its position in LCTX. The position peaked in Q3 2025 at 5.39M shares.
Which other funds hold LCTX?
Other major institutional holders of LCTX include BROADWOOD CAPITAL INC, Defender Capital, LLC., Connective Capital Management, LLC, among 28 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.